Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AKG-100
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Akagera Completes First IV AKG-100 Cohort for Pulmonary Tuberculosis
Details : AKG-100 is a highly stabilized pegylated liposomal formulation of a novel oxazolidinone antibiotic being developed for treatment of pulmonary tuberculosis (TB).
Product Name : AKG-100
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 01, 2025
Lead Product(s) : AKG-100
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
